MA53943A - Modulateurs de ror-gamma - Google Patents

Modulateurs de ror-gamma

Info

Publication number
MA53943A
MA53943A MA053943A MA53943A MA53943A MA 53943 A MA53943 A MA 53943A MA 053943 A MA053943 A MA 053943A MA 53943 A MA53943 A MA 53943A MA 53943 A MA53943 A MA 53943A
Authority
MA
Morocco
Prior art keywords
ror
gamma modulators
modulators
gamma
Prior art date
Application number
MA053943A
Other languages
English (en)
Inventor
David A Claremon
Lawrence Wayne Dillard
Yi Fan
Lanqi Jia
Suresh B Singh
Colin M Tice
Zhenrong Xu
Jing Yuan
Linghang Zhuang
Original Assignee
Vitae Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Llc filed Critical Vitae Pharmaceuticals Llc
Publication of MA53943A publication Critical patent/MA53943A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
MA053943A 2015-11-20 2016-11-17 Modulateurs de ror-gamma MA53943A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257964P 2015-11-20 2015-11-20
US201662320805P 2016-04-11 2016-04-11

Publications (1)

Publication Number Publication Date
MA53943A true MA53943A (fr) 2021-08-25

Family

ID=57589145

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053943A MA53943A (fr) 2015-11-20 2016-11-17 Modulateurs de ror-gamma

Country Status (14)

Country Link
US (1) US11008340B2 (fr)
EP (2) EP3868750A1 (fr)
JP (1) JP6914257B2 (fr)
KR (1) KR20180086221A (fr)
CN (1) CN108463458B (fr)
AU (1) AU2016355710B2 (fr)
BR (1) BR112018010018A2 (fr)
CA (1) CA3005658A1 (fr)
IL (2) IL259421B (fr)
MA (1) MA53943A (fr)
MX (2) MX385332B (fr)
RU (1) RU2018121946A (fr)
SA (1) SA518391624B1 (fr)
WO (1) WO2017087608A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527569B1 (fr) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Inhibiteurs de ror-gamma à base de dihydropyrrolopyridine pour le traitement de l`oeil sec
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CU24487B1 (es) 2015-05-15 2020-11-30 Aurigene Discovery Tech Ltd Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3868750A1 (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
WO2018011747A1 (fr) 2016-07-14 2018-01-18 Cadila Healthcare Limited Composés polycycliques en tant que modulateurs de ror-gamma
EP3481809A1 (fr) 2016-07-14 2019-05-15 Cadila Healthcare Limited Dérivés de cyclopropyle en tant que modulateurs de ror-gamma
WO2018116285A1 (fr) * 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Dérivés de morpholine substitués en tant que modulateurs de ror gamma
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
CN109593068B (zh) * 2017-09-30 2022-12-27 广东东阳光药业有限公司 一种RORγ抑制剂的中间体及其制备方法
TW201922700A (zh) * 2017-10-31 2019-06-16 日商東麗股份有限公司 醯胺苯衍生物及其醫藥用途
EP3749651A1 (fr) * 2018-02-09 2020-12-16 The United States of America, as represented by the Secretary, Department of Health and Human Services Antagonistes hétérocycliques du récepteur p2y14
RU2020131405A (ru) 2018-02-28 2022-03-24 Джапан Тобакко Инк. Сконденсированные с насыщенным кольцом дигидропиримидиноновые или дигидротриазиноновые соединения и их применение в фармацевтике
WO2020082921A1 (fr) * 2018-10-24 2020-04-30 上海和誉生物医药科技有限公司 Dérivé d'azote-hétéroarylamide, son procédé de préparation et son utilisation
AU2019375983A1 (en) 2018-11-09 2021-06-10 Vivace Therapeutics, Inc. Bicyclic compounds
CN113166061B (zh) * 2018-11-27 2023-11-21 正大天晴药业集团股份有限公司 含有磺酰基结构的RORγ抑制剂
CN111484505B (zh) * 2019-01-28 2022-11-15 正大天晴药业集团股份有限公司 一种双环RORγ抑制剂的盐酸盐结晶型
IL287222B2 (en) 2019-04-16 2025-04-01 Vivace Therapeutics Inc Bicyclic compounds
PH12021553110A1 (en) * 2019-06-12 2022-08-01 Tmem16A Ltd Compounds for treating respiratory disease
WO2021047406A1 (fr) * 2019-09-10 2021-03-18 四川科伦博泰生物医药股份有限公司 Composé tricyclique, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
WO2021155320A1 (fr) * 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Composés et leurs utilisations
WO2025223511A1 (fr) * 2024-04-25 2025-10-30 上海翊石医药科技有限公司 Classe de dérivés de benzoylglycine, procédé de préparation et utilisation associés

Family Cites Families (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751524T2 (de) 1986-07-28 1996-06-13 American Cyanamid Co 5(und/oder6) Substituierte 2-(2-Imidazolin-2-yl)nicotinsäuren, Ester und Salze, verwendbar als herbizide Mittel und Zwischenverbindungen für die Herstellung dieser Nikotinsäuren, Ester und Salze.
FR2624698A1 (fr) 1987-12-18 1989-06-23 Bernard Lyon I Universite Clau Derives heterocycliques de n-carbamoyl-, n-thiocarbamoyl- ou n-amidino-aminomalonyl ou aminosuccinyl amides utiles comme agents edulcorants
AU5175490A (en) 1989-02-27 1990-09-26 Du Pont Merck Pharmaceutical Company, The Novel sulfonamides as radiosensitizers
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
EP0520573A1 (fr) 1991-06-27 1992-12-30 Glaxo Inc. Dérivés d'imides cycliques
DE4121214A1 (de) 1991-06-27 1993-01-14 Bayer Ag 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate
US5416099A (en) 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
US5389631A (en) 1991-10-29 1995-02-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5364869A (en) 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
US5326760A (en) 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
JPH06236056A (ja) 1993-02-10 1994-08-23 Fuji Xerox Co Ltd 電子写真感光体
JP3760474B2 (ja) 1993-04-22 2006-03-29 ダイキン工業株式会社 電気エネルギーを発生させる方法、装置およびそれに用いるｎ−ｆ結合を有する化合物
CA2134192A1 (fr) 1993-11-12 1995-05-13 Michael L. Denney Antagonistes iib/iiia de la glycoproteine 5, 6-bicyclique
DE4343922A1 (de) 1993-12-22 1995-06-29 Basf Ag Pyridin-2,3-dicarbonsäureimide, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
KR970007419B1 (ko) 1993-12-30 1997-05-08 한솔제지 주식회사 승화형 열전사 기록용 색소
FR2725946A1 (fr) 1994-10-24 1996-04-26 Lohr Ind Cale a rapporter sur un plan porteur presentant des perforations
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
TW394773B (en) 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5770590A (en) 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
EP0882718B1 (fr) 1995-12-28 2005-08-31 Fujisawa Pharmaceutical Co., Ltd. Derives du benzimidazole
DE19608791A1 (de) 1996-03-07 1997-09-11 Hoechst Ag Verfahren zur Herstellung von fluorierten Aromaten und fluorierten stickstoffhaltigen Heteroaromaten
DE19702282C2 (de) 1997-01-23 1998-11-19 Hoechst Ag Katalysator für Halex-Reaktionen
EP0973778A1 (fr) 1997-03-07 2000-01-26 Novo Nordisk A/S DERIVES DE 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE, LEUR PREPARATION ET LEUR UTILISATION
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
KR19980074060A (ko) 1997-03-21 1998-11-05 김윤배 신규한 치환된 3,4-디알콕시페닐 유도체
JPH1143489A (ja) 1997-05-30 1999-02-16 Takeda Chem Ind Ltd ヘテロ環化合物、その製造法および剤
US20020132817A1 (en) 1998-03-19 2002-09-19 Hideaki Natsugari Heterocyclic compounds, their production and use
KR20010041991A (ko) 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2000007661A (ja) 1998-06-23 2000-01-11 Nippon Nohyaku Co Ltd 複素環ジカルボン酸ジアミド誘導体及びその中間体並びに除草剤
WO2000006549A1 (fr) 1998-07-28 2000-02-10 Nihon Nohyaku Co., Ltd. Derives de diamide dicarboxylique a heterocycle condense ou sels de ceux-ci, herbicides et leur utilisation
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU1409100A (en) 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
KR100718830B1 (ko) 1999-06-23 2007-05-17 사노피-아벤티스 도이칠란트 게엠베하 치환된 벤즈이미다졸 및 이의 제조방법
TR200200118T2 (tr) 1999-07-21 2002-12-23 Astrazeneca Ab Yeni bileşimler
DK1206436T3 (da) 1999-08-02 2005-02-14 Hoffmann La Roche Retinoider til behandling af emfysem
US6512117B1 (en) 1999-11-09 2003-01-28 Abbott Laboratories Hydromorphone and hydrocodone compositions and methods for their synthesis
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1162196A4 (fr) 1999-12-27 2003-04-16 Japan Tobacco Inc Composes a cycles accoles et leur utilisation comme medicaments
WO2001051128A1 (fr) 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibiteurs de la prenyl-transferase
WO2001083445A1 (fr) 2000-04-25 2001-11-08 Samsung Electronics Co., Ltd. Derives d'acide diphenylbutyrique inhibiteurs de metalloproteinase matricielle
CA2407189A1 (fr) 2000-05-02 2001-11-08 F. Hoffmann-La Roche Ag Nouveaux retinoides selectifs gamma
CA2408156A1 (fr) 2000-05-05 2001-11-15 Millennium Pharmaceuticals, Inc. Sulfonamides heterobicycliques et utilisation de celles-ci comme inhibiteurs de recepteur adp des plaquettes
US6552015B2 (en) 2000-08-03 2003-04-22 Pfizer Inc. Azabicycloalkane derivatives and therapeutic uses thereof
WO2002024650A2 (fr) 2000-09-19 2002-03-28 Centre National De La Recherche Scientifique (Cnrs) Derives de pyridinone et de pyridinethione presentant des proprietes inhibitrices du vih
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2002081447A1 (fr) 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. Derives de 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone et utilisation de ces derives
EP1767525A1 (fr) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Composés guanidino comme agonistes du récepteur 4 de la mélanocortine (MC4-R)
US7476688B2 (en) 2001-04-19 2009-01-13 Eisai R&D Management Co., Ltd. Cyclic amidine derivatives
HRP20030961B1 (en) 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
KR20040027878A (ko) 2001-07-16 2004-04-01 시오노기 앤드 컴파니, 리미티드 아미딘 유도체의 제조 방법
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
WO2003029254A1 (fr) 2001-09-28 2003-04-10 Takeda Chemical Industries, Ltd. Procede de preparation de composes tricycliques
JP2003171380A (ja) 2001-09-28 2003-06-20 Takeda Chem Ind Ltd 三環性化合物の製造法
EP1432707B1 (fr) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AU2003213266A1 (en) 2002-03-06 2003-09-22 Smithkline Beecham Corporation Condensed heterocyclic compounds as calcitonin agonists
US20040077529A1 (en) 2002-06-10 2004-04-22 Per-Fredrik Lehmann Urotensin II receptor agents
AU2003250482A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
EP1543001B1 (fr) * 2002-09-17 2007-08-15 Eli Lilly And Company Derives de pyrazolopyridine en tant qu'inhibiteurs de tgf-beta pour le traitement des maladies de cancer
WO2004043979A2 (fr) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Composes oligomeres contenant un substitut de sucre et compositions a utiliser dans la modulation genique
JP2004203791A (ja) 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
CN1212674C (zh) 2003-01-08 2005-07-27 东南大学 横向缓冲p型金属氧化物半导体管
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
CN1787817B (zh) 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
WO2004113330A1 (fr) 2003-05-19 2004-12-29 Irm Llc Compositions et composes immunosuppresseurs
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
EP1628661A2 (fr) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulateurs du recepteur vr1
CN1566099A (zh) 2003-06-13 2005-01-19 中国科学院上海药物研究所 异喹啉－1,3,4－三酮类化合物、制备方法及其用途
WO2005005392A1 (fr) 2003-07-07 2005-01-20 Ionix Pharmaceuticals Limited Composes azacycliques convenant comme inhibiteurs des canaux specifiques des neurones sensoriels
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
BRPI0413245A (pt) 2003-08-01 2006-10-03 Pfizer Prod Inc compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
WO2005028480A2 (fr) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, et pyrazines et composes associes
BRPI0414087A (pt) 2003-09-05 2006-10-31 Neurogen Corp composto, métodos para tratar um distúrbio, para demostrar a presença de receptores de crf em amostras de célula ou tecido, e para inibir a ligação de crf a um receptor de crf1, composição farmacêutica, e, embalagem
WO2005025504A2 (fr) 2003-09-12 2005-03-24 Kemia, Inc. Modulateurs de l'activite de la calcitonine et de l'amyline
WO2005039564A1 (fr) 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Composes phtalimide utiles en tant qu'inhibiteurs de proteine kinase
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
NZ547481A (en) 2003-11-19 2009-12-24 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
US20050203151A1 (en) 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
CA2549638A1 (fr) 2003-12-23 2005-07-14 Pfizer Products Inc. Combinaison therapeutique d'amelioration neuro-cognitive et de traitement de troubles psychotiques
JP2007531744A (ja) * 2004-04-05 2007-11-08 武田薬品工業株式会社 ６−アザインドール化合物
WO2005100334A1 (fr) 2004-04-14 2005-10-27 Pfizer Products Inc. Inhibiteurs de dipeptidyl peptidase-iv
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
SI1809622T1 (sl) 2004-09-22 2010-11-30 Janssen Pharmaceutica Nv Inhibitorji interakcije med MDM in P
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006065842A2 (fr) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinoleines et composes associes et leurs utilisations
RU2007130077A (ru) 2005-01-07 2009-02-20 Эмори Юниверсити (Us) Антагонисты cxcr4 и их применение для лечения вич-инфекции
UA91536C2 (uk) 2005-02-07 2010-08-10 Ф. Хоффманн-Ля Рош Аг Гетероциклічні заміщені фенілметанони як інгібітори переносника гліцину 1
GB0504556D0 (en) 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
US20080306054A1 (en) 2005-04-13 2008-12-11 Astex Therapeutics Limited Pharmaceutical Compounds
WO2007050124A1 (fr) 2005-05-19 2007-05-03 Xenon Pharmaceuticals Inc. Derives fusionnes de piperidine et leurs utilisations en tant qu'agents therapeutiques
WO2007007054A1 (fr) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides, composes apparentes et leur utilisation en tant que produits pharmaceutiques
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
ES2363795T3 (es) 2005-09-29 2011-08-16 Glaxo Group Limited Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de pde4.
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
PE20071240A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
WO2007087231A2 (fr) 2006-01-25 2007-08-02 Merck & Co., Inc. Aminocyclohexanes utiles en tant qu'inhibiteurs de la dipeptidyl peptidase-iv pour traiter ou prévenir le diabète
JP5161795B2 (ja) 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
AU2007220039A1 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of the unfolded protein response and methods for their use
ATE470665T1 (de) 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
US7977351B2 (en) 2006-03-22 2011-07-12 Allergan, Inc. Heteroaryl dihydroindolones as kinase inhibitors
US7700616B2 (en) 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
PE20080702A1 (es) 2006-05-16 2008-07-10 Boehringer Ingelheim Int PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
CN1869036A (zh) 2006-06-30 2006-11-29 中国药科大学 7－取代－3－氯吡咯并[3,4－b]吡啶化合物
DE102006032824A1 (de) 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
CA2657287A1 (fr) * 2006-07-17 2008-01-24 Merck & Co., Inc. Composes de 1-hydroxy naphtyridine en tant qu'agents anti-vih
EP2051964A4 (fr) 2006-07-28 2012-03-07 Univ Connecticut Inhibiteurs d'amide d'acide gras hydrolase
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
WO2008044027A2 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Composés pharmaceutiques
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073865A2 (fr) 2006-12-11 2008-06-19 Novartis Ag Procédé de traitement
WO2008083070A1 (fr) 2006-12-29 2008-07-10 Neurogen Corporation Ligands des récepteurs du crf1 comprenant des groupes fonctionnels hétéroaryle bicycliques
KR20090101372A (ko) 2007-01-08 2009-09-25 페노믹스 코포레이션 매크로시클릭 ｃ형 간염 프로테아제 억제제
WO2009004496A2 (fr) 2007-04-13 2009-01-08 University Of Manitoba Bisanthrapyrazoles comme agents anticancer
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
US20100129933A1 (en) 2007-04-26 2010-05-27 Forschungszentrum Karlsruhe Gmbh Method for detecting the binding between mdm2 and the proteasome
WO2008135524A2 (fr) 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Anthranilamides substitués et analogues, leur fabrication et utilisation en tant que médicaments
AR066379A1 (es) 2007-05-02 2009-08-12 Boehringer Ingelheim Int Amidas de acido carboxilico su preparacion y su uso como medicamentos
DK2152794T3 (da) 2007-05-10 2014-03-31 Constar Internat Llc Oxygen-fjernende molekyler, artikler indeholdende disse, og fremgangsmåde til deres anvendelse
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
WO2009026248A2 (fr) 2007-08-17 2009-02-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Analogues d'hydrazide, d'amide, de phtalimide et de phtalhydrazide en tant qu'inhibiteurs de l'intégrase rétrovirale
TWI534137B (zh) 2007-09-17 2016-05-21 艾伯維巴哈馬有限公司 抗感染劑及其用途
US20090076275A1 (en) 2007-09-19 2009-03-19 David Robert Bolin Diacylglycerol acyltransferase inhibitors
US20100210655A1 (en) 2007-10-11 2010-08-19 Yun Ding NOVEL sEH INHIBITORS AND THEIR USE
EP2203058A4 (fr) 2007-10-16 2011-08-31 Univ Northeastern Procédés et composés permettant la modulation de l'activité cannabinoïde
US20100261679A1 (en) 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
CN101874019B (zh) 2007-11-29 2013-06-12 弗·哈夫曼-拉罗切有限公司 制备异吲哚衍生物的方法以及制备它们的中间体的方法
WO2009073788A1 (fr) 2007-12-07 2009-06-11 Firestone Leigh H Compositions et procédés pour traiter des femmes ménopausées
EP2078711A1 (fr) 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Dérivés (aza)indole substitués en position 5, compositions pharmaceutiques, composés intermédiaires et procédé de préparation
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
CN101225070B (zh) 2008-01-31 2010-04-14 上海交通大学 用于抗肿瘤的药物
SI2242740T1 (sl) 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
WO2009112445A1 (fr) 2008-03-10 2009-09-17 Novartis Ag Procédé d’accroissement de phosphatidyl-choline des cellules par l’inhibition de la dgat1
GB0804702D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
WO2009124755A1 (fr) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Composés à nouvelles utilisations médicales et procédés d'identification de ces composés
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
US8309577B2 (en) 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
GB0809776D0 (en) 2008-05-29 2008-07-09 Amura Therapeutics Ltd Compounds
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
EP2327704A4 (fr) 2008-08-29 2012-05-09 Shionogi & Co Dérivé azole à cycles condensés possédant une activité inhibitrice de pi3k
WO2010033350A1 (fr) 2008-09-16 2010-03-25 Merck & Co., Inc. Ligands du glutamate métabotropique r4 dérivé de sulfonamide
US20100125081A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20100125087A1 (en) 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
CN101455661B (zh) 2008-11-19 2012-10-10 中国科学院上海有机化学研究所 3-取代苯酞及其类似物的用途
CN106336400A (zh) 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
EP2391608B8 (fr) 2009-01-28 2013-04-10 Bayer Intellectual Property GmbH Dérivés fongicides du n-cycloalkyl-n-bicyclicméthylène -carboxamide
WO2011078143A1 (fr) 2009-12-22 2011-06-30 塩野義製薬株式会社 Dérivés de pyrimidine et composition pharmaceutique les contenant
CA2785791A1 (fr) 2010-01-19 2011-07-28 Research Triangle Institute Ligands de liaison de recepteur opioide kappa
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
EP2368886A1 (fr) 2010-03-01 2011-09-28 Phenex Pharmaceuticals AG Nouveaux composés pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies chroniques et maladies auto-immunes
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2801182A1 (fr) 2010-06-16 2011-12-22 Metabolex, Inc. Agonistes du recepteur gpr120 et leurs utilisations
WO2012027965A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
WO2012028100A1 (fr) 2010-09-01 2012-03-08 Glaxo Group Limited Nouveaux composés
WO2012031197A1 (fr) 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Nouveaux composés et compositions pour l'inhibition de nampt
CN103119035B (zh) 2010-09-27 2015-09-30 雅培股份有限两合公司 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途
JP2013253019A (ja) 2010-09-28 2013-12-19 Kowa Co 新規なピペリジン誘導体及びこれを含有する医薬
JP6063870B2 (ja) 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
CA2816769A1 (fr) 2010-11-10 2012-05-18 Gruenenthal Gmbh Carboxamide heteroaromatique substitue et derives de l'uree en tant que ligands du recepteur vanilloide
WO2012100734A1 (fr) 2011-01-24 2012-08-02 Glaxo Group Limited Composés utiles en tant que modulateurs du récepteur apparenté au récepteur des rétinoïdes gamma
WO2012100732A1 (fr) 2011-01-24 2012-08-02 Glaxo Group Limited Modulateurs des récepteurs orphelins gamma apparentés au récepteur des rétinoïdes, composition les contenant et utilisations associées
EP2487159A1 (fr) 2011-02-11 2012-08-15 MSD Oss B.V. Inhibiteurs du RORgammaT
CN102180780A (zh) 2011-03-07 2011-09-14 中国科学技术大学 茚酮类衍生物及其作为淀粉样蛋白沉积物和神经纤维缠结的显像剂和聚集抑制剂的用途
EP2686305B1 (fr) 2011-03-14 2020-09-16 Impact Therapeutics, Inc. Quinazolinediones et leur utilisation
CN103635458B (zh) 2011-03-25 2016-10-19 艾伯维公司 Trpv1拮抗剂
US9469667B2 (en) 2011-04-04 2016-10-18 Merck Patent Gmbh Metal complexes
EP2511263A1 (fr) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Composés de pyrrolo sulfonamide pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies inflammatoires et de maladies auto-immunes chroniques
EP2927217B1 (fr) 2011-04-28 2018-01-17 Japan Tobacco Inc. Composé d'amide et son application pharmaceutique
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013019653A1 (fr) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et méthodes
US20140315881A1 (en) 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
US20140155419A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
EP2747560A4 (fr) 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc Composés et méthodes
WO2013018695A1 (fr) 2011-07-29 2013-02-07 武田薬品工業株式会社 Composé hétérocyclique
WO2013029338A1 (fr) 2011-09-01 2013-03-07 Glaxo Group Limited Nouveaux composés
US9120776B2 (en) 2011-09-22 2015-09-01 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
WO2013078233A1 (fr) 2011-11-22 2013-05-30 Ripka Amy S Modulateurs n-benzylbenzimidazoles de pparg
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
WO2013092460A1 (fr) 2011-12-20 2013-06-27 Syngenta Participations Ag Microbicides bisoximes cycliques
US9567328B2 (en) 2011-12-21 2017-02-14 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9216988B2 (en) 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
US20130190356A1 (en) 2011-12-22 2013-07-25 Genentech, Inc. Benzyl sulfonamide derivatives as rorc modulators
WO2013100027A1 (fr) 2011-12-28 2013-07-04 武田薬品工業株式会社 Composé hétérocyclique
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
GB201207406D0 (en) 2012-04-27 2012-06-13 Glaxo Group Ltd Novel compounds
CN104379559B (zh) 2012-04-27 2016-11-09 葛兰素集团有限公司 化合物
EP2844259A4 (fr) 2012-04-30 2015-11-11 Anderson Gaweco Modulateurs de ror et leurs utilisations
AU2013259904A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Bicyclic sulfone compounds for inhibition of RORy activity and the treatment of disease
MX367341B (es) 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
WO2013169864A2 (fr) 2012-05-08 2013-11-14 Lycera Corporation Tétrahydro[1,8]naphtyridine-sulfonamide et composés apparentés pour utilisation en tant qu'agonistes de rorγ et dans le traitement d'une maladie
NZ702539A (en) 2012-05-31 2016-11-25 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
WO2014008214A1 (fr) 2012-07-02 2014-01-09 Biogen Idec Ma Inc. Composés contenant biaryle comme agonistes inverses de récepteurs ror-gamma
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
WO2014026329A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'indazole et d'indole n-alkylés en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2014026327A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2014026330A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés 3-aminocycloalkyles en tant qu'inhibiteurs de rorgammat et leurs utilisations
WO2014028669A1 (fr) 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Nouveaux composés pour la modulation de l'activité ror-gamma
WO2014026328A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'indazole et d'indole à substitution 3-cyclohexényle en tant qu'inhibiteurs de rorgammat et leurs utilisations
ES2623528T3 (es) 2012-09-21 2017-07-11 Sanofi Derivados de amida de ácido benzoimidazolcarboxílico para tratar enfermedades metabólicas o cardiovasculares
WO2014062938A1 (fr) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Modulateurs du récepteur gamma orphelin associé aux rétinoïdes (rory)
AR093818A1 (es) * 2012-12-06 2015-06-24 Glaxo Group Ltd Compuesto de 1-(bencil sustituido)piperazina sustituida
WO2013171729A2 (fr) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Composés d'aryl- et hétéroarylamide en tant que modulateur de rorγt
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
WO2014179564A1 (fr) * 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Inhibiteurs du ror-gamma à base de thiazalopyrrolidine
EP3027616B1 (fr) * 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Composés d'azaindole à titre de modulateurs de rorc
JP6501782B2 (ja) 2013-09-05 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒガンマのモジュレーターとしての二環式化合物
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
CA2929194A1 (fr) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag Derives de 5,6,7,8-tetrahydro-5,8-methanocinnoline a titre de modulateurs rorc pour le traitement des maladies auto-immunes
WO2015083130A1 (fr) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Pyridine et dérivés de pyrimidine à l'état fondu à titre de modulateurs ror gamma
CA2934819A1 (fr) 2013-12-24 2015-07-02 President And Fellows Of Harvard College Analogues de cortistatine et syntheses et utilisations associees
JP2015124178A (ja) 2013-12-26 2015-07-06 東レ株式会社 環状アミン誘導体及びその医薬用途
WO2015101928A1 (fr) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Dérivés de thiophène et de thiazole fusionnés utilisés en tant que modulateurs gamma ror
PE20161239A1 (es) 2014-02-03 2016-11-09 Basf Se Compuesto de ciclopenteno y ciclopentadieno para controlar plagas de invertebrados
EP3527569B1 (fr) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Inhibiteurs de ror-gamma à base de dihydropyrrolopyridine pour le traitement de l`oeil sec
BR112016020117B1 (pt) 2014-03-26 2020-03-17 Basf Se “compostos, composição e método para o combate dos fungos fitopatogênicos
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EP3122751B1 (fr) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Composés condensés de [1,4]diazépine en tant qu'inhibiteurs d'autotaxine (atx) et de production d'acide lysophosphatidique (lpa)
AP2016009542A0 (en) 2014-04-16 2016-11-30 Glenmark Pharmaceuticals Sa Aryl and heteroaryl ether compounds as ror gamma modulators
TWI675032B (zh) 2014-10-14 2019-10-21 美商維它藥物公司 ＲＯＲ-γ之二氫吡咯并吡啶抑制劑
EP3209299A4 (fr) * 2014-10-22 2018-04-04 The Board of Regents of The University of Texas System Inhibiteurs à petites molécules ciblant le récepteur du domaine discoïdine 1 et ses utilisations
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN112608300B (zh) * 2015-03-11 2024-04-26 Fmc公司 杂环取代的二环唑杀有害生物剂
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3868750A1 (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (fr) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibiteurs de ror gamma

Also Published As

Publication number Publication date
AU2016355710A1 (en) 2018-05-31
WO2017087608A8 (fr) 2017-07-06
IL259421A (en) 2018-07-31
CA3005658A1 (fr) 2017-05-26
EP3377482B1 (fr) 2021-05-12
SA518391624B1 (ar) 2021-06-13
IL283582A (en) 2021-07-29
IL259421B (en) 2021-06-30
RU2018121946A3 (fr) 2020-04-16
JP2018534326A (ja) 2018-11-22
EP3377482A1 (fr) 2018-09-26
RU2018121946A (ru) 2019-12-23
CN108463458A (zh) 2018-08-28
AU2016355710B2 (en) 2021-03-25
JP6914257B2 (ja) 2021-08-04
WO2017087608A1 (fr) 2017-05-26
MX2021009673A (es) 2021-09-08
US11008340B2 (en) 2021-05-18
MX2018006223A (es) 2018-12-19
CN108463458B (zh) 2022-02-01
US20190322687A1 (en) 2019-10-24
MX385332B (es) 2025-03-18
EP3868750A1 (fr) 2021-08-25
KR20180086221A (ko) 2018-07-30
BR112018010018A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
NL301311I2 (nl) sugemalimab
FIC20230006I1 (fi) Vutrisiraani
MA55328A (fr) Modulateurs de ror-gamma
MA42061A (fr) Modulateurs de k-ras
MA43382A (fr) Modulateurs des récepteurs des chimiokines
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3286361A4 (fr) Néo-épitopes de cancer
DK3331869T3 (da) Muscarinagonister
DK3297438T3 (da) Ccr2-modulatorer
DK3331876T3 (da) Modulators of ror-gamma
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (fr) Cuve à circulation d'oxydoréduction
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (fr) Système de surveillance d'usure de bande transporteuse
DK3310450T3 (da) Olie-vand-separator
DK3394281T3 (da) Gærcelle
DK3270930T3 (da) Præeklampsi
EP3363322A4 (fr) Extension de cheveux
DK3292136T3 (da) Penicillin-g-acylaser
DK3274482T3 (da) Stenborsknop
EP3532062A4 (fr) Modulateurs de ror-gamma
DE112015006486A5 (de) Inkubationsrinne